Delivery Order SPE2DB22D2214-SPE2DB25FS6BT
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $5,996.73 to AmerisourceBergen Drug Corp for the supply of Ondansetron ODT 4 mg tablets in quantities of 30 units. This competitively awarded, firm fixed-price delivery order was executed on August 14, 2025, with an ultimate completion date of August 15, 2025. The contract does not include a set-aside designation. Performance will be fulfilled from AmerisourceBergen's location in Conshohocken, Pennsylvania. This delivery order is...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 8, 2025, for the supply of Ondansetron ODT 4 mg tablets in quantities of 30, with a contract ceiling value of $1,961.44. This firm fixed price delivery order is non-competitive and represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical valued at $999.99 billion through December 2026. The work will be performed at...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $12,579.01 to AmerisourceBergen Drug Corp for Ondansetron ODT 4 mg tablets (30-count units) with an ultimate completion date of August 15, 2025. This firm fixed-price delivery order, awarded on August 14, 2025, represents a non-set-aside competitive award. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. This...
- The Defense Logistics Agency awarded a $5,629.86 delivery order to AmerisourceBergen Drug Corp for Ondansetron ODT 4 mg tablets (30-count supply) on July 24, 2025, with an ultimate completion date of July 25, 2025. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded through open competition. The place of performance is located in Conshohocken, Pennsylvania, which is also the headquarters location of the prime contractor. This delivery order is issued...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of Ondansetron ODT 4 mg tablets in quantities of 30 units. This is a firm fixed-price delivery order valued at $11,862.80, with an ultimate completion date of August 15, 2025. The order was competitively awarded with no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued...
- The Defense Logistics Agency awarded a delivery order valued at $1,084.74 to AmerisourceBergen Drug Corp for the supply of Ondansetron ODT 4 mg tablets (30 count) under a firm fixed-price contract. The award was made on August 13, 2025, with an ultimate completion date of August 14, 2025. This non-set-aside contract represents a routine pharmaceutical procurement for military medical supply needs, with performance to be fulfilled at the contractor's facility in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on August 1, 2025, for the supply of Ondansetron ODT 4 mg tablets (30-count units) with a contract ceiling value of $3,874.25. This is a firm fixed-price delivery order with an ultimate completion date of August 4, 2025, and represents a non-competitive set-aside award. The place of performance is AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. This delivery order is issued...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $16,113.82 to AmerisourceBergen Drug Corp for the supply of Ondansetron ODT 4 mg tablets in a 30-count configuration. This contract is classified as firm fixed price with no set-aside designation, indicating it was competitively awarded. The delivery order is set for ultimate completion on August 18, 2025, and will be performed at AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania. This award...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Ondansetron ODT 4 mg tablets (30-count packages) with a firm fixed price ceiling value of $11,979.29. The contract, awarded on August 12, 2025, with an ultimate completion date of August 13, 2025, represents a non-competitive, non-set-aside delivery order. Performance will be executed from AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 23, 2025, for the supply of Ondansetron ODT 4 mg tablets (30-count units) with a ceiling value of $8,001.71. This is a firm fixed price, non-competitive delivery order executed under the company's broader Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion global pharmaceutical support vehicle running through December 2026. The order will be performed at...
- SPE2DB22D2214Indefinite Delivery Contract
- SPE2DB22D2214-SPE2DB25FS6BTDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $49,146.24 to AmerisourceBergen Drug Corp for the supply of Ondansetron ODT 4 mg tablets (30-count units). This firm fixed-price delivery order, awarded on August 8, 2025, with an ultimate completion date of August 11, 2025, represents a direct purchase of pharmaceutical inventory from the vendor's Conshohocken, Pennsylvania facility. The award utilized no set-aside designation, indicating AmerisourceBergen Drug Corp was selected through open competition to fulfill this medical supply requirement. This delivery order operates as a child contract under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. This comprehensive IDC vehicle enables the company to supply a broad portfolio of pharmaceutical products and medical supplies to support military healthcare programs globally. Ondansetron, a commonly utilized antiemetic medication, represents one of many pharmaceutical commodities delivered under this framework to support Defense Health Agency operations and other federal healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $49.1k | 8/8/25 |